A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, Versus Investigator's Choice Chemotherapy in Women With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT05613088

Title field or adapter rule

{'original_value': "A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, Versus Investigator's Choice Chemotherapy in Women With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer", 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:29.952240+00:00

Published At

2025-07-03T00:00:00+00:00

Record Updated At

2026-10-28

Results Posted At

2025-07-03

Source Retrieved At

2026-10-31T22:18:15.087634+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Neoplasms, Ovarian"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-28", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT05613088"

protocolSection.identificationModule.officialTitle

"A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, Versus Investigator\u0027s Choice Chemotherapy in Women With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer"

protocolSection.statusModule.overallStatus

"TERMINATED"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

{"date": "2025-07-03", "type": "ACTUAL"}

Study condition terms

• Neoplasms, Ovarian (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['MORAb-202'], 'description': 'Specified dose on specified days', 'name': 'MORAb-202', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ["Investigator's Choice Chemotherapy"], 'description': 'Specified dose on specified days', 'name': 'Paclitaxel', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ["Investigator's Choice Chemotherapy"], 'description': 'Specified dose on specified days', 'name': 'Pegylated Liposomal Doxorubicin (PLD)', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ["Investigator's Choice Chemotherapy"], 'description': 'Specified dose on specified days', 'name': 'Topotecan', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• MORAb-202 (protocolSection.armsInterventionsModule.interventions[].name)
• Paclitaxel (protocolSection.armsInterventionsModule.interventions[].name)
• Pegylated Liposomal Doxorubicin (PLD) (protocolSection.armsInterventionsModule.interventions[].name)
• Topotecan (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.